Insurers Restrict Coverage of GLP-1 Drugs to Diabetes Treatment Only
β’ Major U.S. health insurers are limiting coverage of GLP-1 drugs like Ozempic and Wegovy to their original FDA-approved use for diabetes management, excluding weight loss treatments. β’ According to industry analyst Andy, this shift reverses prior expansions amid rising costs and supply shortages, affecting millions of patients seeking obesity care. β’ The policy change aims to control spending on these high-demand medications, which have seen off-label use surge, potentially pushing patients toward alternatives or out-of-pocket payments.
Read original Β· healthcareittoday.com
Healthcare IT Today



